These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19475497)

  • 1. Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation.
    Mian C; Barollo S; Zambonin L; Pennelli G; Bernante P; Pelizzo MR; Nacamulli D; Mantero F; Girelli ME; Opocher G
    Fam Cancer; 2009; 8(4):379-82. PubMed ID: 19475497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
    Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
    Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
    Frank-Raue K; Rybicki LA; Erlic Z; Schweizer H; Winter A; Milos I; Toledo SP; Toledo RA; Tavares MR; Alevizaki M; Mian C; Siggelkow H; Hüfner M; Wohllk N; Opocher G; Dvořáková S; Bendlova B; Czetwertynska M; Skasko E; Barontini M; Sanso G; Vorländer C; Maia AL; Patocs A; Links TP; de Groot JW; Kerstens MN; Valk GD; Miehle K; Musholt TJ; Biarnes J; Damjanovic S; Muresan M; Wüster C; Fassnacht M; Peczkowska M; Fauth C; Golcher H; Walter MA; Pichl J; Raue F; Eng C; Neumann HP;
    Hum Mutat; 2011 Jan; 32(1):51-8. PubMed ID: 20979234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.
    Castro MR; Thomas BC; Richards ML; Zhang J; Morris JC
    Thyroid; 2013 Dec; 23(12):1547-52. PubMed ID: 23461807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by the D631Y RET Mutation.
    Ospina NS; Maraka S; Donegan D; Morris JC
    Thyroid; 2017 Oct; 27(10):1332-1334. PubMed ID: 28747092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET codon 609 mutations: a contribution for better clinical managing.
    Mian C; Sartorato P; Barollo S; Zane M; Opocher G
    Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):33-6. PubMed ID: 22584703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients.
    Imai T; Uchino S; Okamoto T; Suzuki S; Kosugi S; Kikumori T; Sakurai A;
    Eur J Endocrinol; 2013 May; 168(5):683-7. PubMed ID: 23416954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A comparison of clinical characteristics between 2 pedigrees of multiple endocrine neoplasia type 2A with different RET mutations].
    Weng Y; Xue SN; Zhang SL; Cheng H; Yan L
    Zhonghua Nei Ke Za Zhi; 2018 Feb; 57(2):134-137. PubMed ID: 29397600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
    Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
    Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?
    Gimm O; Niederle BE; Weber T; Bockhorn M; Ukkat J; Brauckhoff M; Thanh PN; Frilling A; Klar E; Niederle B; Dralle H
    Surgery; 2002 Dec; 132(6):952-9; discussion 959. PubMed ID: 12490841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple endocrine neoplasia type 2.
    Wohllk N; Schweizer H; Erlic Z; Schmid KW; Walz MK; Raue F; Neumann HP
    Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):371-87. PubMed ID: 20833330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-specific development of MEN 2 constituent components in 683 RET carriers.
    Machens A; Lorenz K; Weber F; Brandenburg T; Führer-Sakel D; Dralle H
    Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38753300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Homozygous RET K666N Genotype With an MEN2A Phenotype.
    Jaber T; Hyde SM; Cote GJ; Grubbs EG; Giles WH; Stevens CA; Dadu R
    J Clin Endocrinol Metab; 2018 Apr; 103(4):1269-1272. PubMed ID: 29408964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pheochromocytoma as the first manifestation of MEN2A with RET mutation S891A: report of a case.
    Hibi Y; Ohye T; Ogawa K; Shimizu Y; Shibata M; Kagawa C; Mizuno Y; Uchino S; Kosugi S; Kurahashi H; Iwase K
    Surg Today; 2014 Nov; 44(11):2195-200. PubMed ID: 24449023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.